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Abstract
Background: Because of its high rate of early recurrence and its poor prognosis, long-term survival after
cholangiocarcinoma is rare; therefore, only limited information on patients surviving more than 5 years after
surgical therapy is available.
Case presentation: We report the case of a 57-year-old white man who developed a distal bile duct carcinoma 9 years
after curative surgical therapy of intrahepatic cholangiocarcinoma. He had undergone a right lobe hemihepatectomy 11
years ago. Nine years later, he was diagnosed with a distal bile duct carcinoma and a duodenopancreatectomy was
performed. On histologic examination both carcinomas revealed a tubular and papillary growth pattern with cancer-free
resection margins and for both carcinomas there were no signs of lymphatic infiltration or metastatic spreading. Targeted
next-generation sequencing showed an identical activating mutation pattern in both carcinomas.
Conclusions: Late recurrence of cholangiocarcinoma, even anatomically distant to the primary, in long-time survivors is
possible and could be caused by a distinct tumor biology. A better understanding of the individual tumor biology could
help hepatologists as well as hepatobiliary and pancreatic surgeons in their daily treatment of these patients.
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Background
Cholangiocarcinomas (CCA) account for 3 % of all
gastrointestinal tumors [1], with an estimated 5-year-
survival rate of approximately 10 % [2, 3].
According to their anatomical localization they are
classified as intrahepatic (iCCA), perihilar (pCCA), and
distal (dCCA) carcinomas [4]. In a large study of 564
patients, 8 % of patients had iCCA, 50 % had pCCA,
and 42 % had dCCA [5]. Whereas pCCA and dCCA
arise from biliary epithelium and peribiliary glands,
iCCA derive either from biliary epithelium or from hep-
atic progenitor cells [1].
In Western countries, common risk factors for CCA are
primary sclerosing cholangitis (PSC), inflammatory bowel
disease, alcohol, tobacco smoking, fatty liver disease, dia-
betes, cholelithiasis, and choledocholithiasis; the common
risk factor for iCCAs is viral hepatitis. Furthermore, there
are gene variations, which might have the potential to en-
hance carcinoma development [3, 6, 7].
The only available curative treatment option is surgical
resection with negative margins. Depending on the
localization, there are also options for neoadjuvant, adju-
vant, and palliative chemotherapy, radiation, ablative treat-
ment, and even liver transplant [8]. The rates of 5-year
survival in patients with pCCA and dCCA after surgical
therapy with negative margins range from 24 to 43 % and
27 % [5], respectively. Compared to that, the overall 5-year
survival rate for all stages and treatment options is less than
5 % [9, 10]. Independent factors influencing long-term sur-
vival after surgery are the pathological metastases classifica-
tion (pM), the ductal margin status, and the size of the
primary tumor and its histological grading [11].
Due to the reported low survival rates there are only a
few patients who develop a secondary CCA. If recurrence
occurs, it needs to be differentiated between recurrence as
metastatic disease, a locoregional relapse, probably due to
residual cells after the first operation or a second primary
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Eleven years ago, a 46-year-old white man presented
with painless jaundice. He showed no other symptoms
and had no risk factors such as high alcohol consump-
tion or tobacco smoking. With a bodyweight of 73 kg
and a height of 175 cm his body mass index (BMI) was
24.49 kg/m2 at the time of presentation. His mother had
colorectal cancer otherwise there was no family history.
Diagnostics
An endosonography showed an intraluminal polypoid
tumor with disintegration of all wall layers at the
bifurcation of his bile duct system. The finding was
confirmed by endoscopic retrograde cholangiopan-
creatography (ERCP). Biopsies were taken with the
pathologic results coming back inconclusive.
Computed tomography showed an intrahepatic chole-
stasis and two hypodense lesions in segment VIII of his
liver. It showed no signs of metastasis or other unknown
pathologies. The analysis of serum tumor marker carci-
noembryonic antigen (CEA) was negative and cancer
antigen (CA) 19-9 was found to be elevated at 75 kU/l
(<37 kU/l).
Treatment
He was treated with right liver lobectomy with resection
of the bile duct directly distal of his pancreatic head,
resection of the bile duct of his left liver lobe up to the
first intersection, and with a regional lymphadenectomy.
The reconstruction was performed by biliodigestive
anastomosis with Roux-en-Y hepaticojejunostomy. A
bile duct drain was inserted in the dorsal bile duct of his
left lobe and closed on day 10 after contrast imaging of
the anastomosis. Postoperatively, he recovered well. On
the planned day of discharge he developed an aphasia
leading to further diagnostics, which showed a transito-
ric ischemic attack of his left-brain hemisphere. He was
transferred to neurology and fully recovered.
Pathology
A gross examination showed a right hemihepatectomy
with a 4×2×2 cm polypoid tumor in his right hepatic
bile duct extending into the bile duct junction (mainly
intraductal growth type). The liver parenchyma was
non-cirrhotic and prominent portal tracts were seen.
Resection margins were free of tumor.
Histologic examination revealed an intraductal tumor
with tubular and papillary and solid growth pattern. There
was a stromal invasion into the ductus hepaticus dexter.
In the portal tracts intraductal tumor growth without stro-
mal invasion was found (Fig. 1). According to TNM classi-
fication the tumor staging was pT1 pN0 (0/4) M0 R0, G2.
Bile duct cholangiocarcinoma
Patient history
The same patient presented 2 years ago at the age of 55
with a mass of 1.8×2.4 cm at the papilla of Vater. The
mass was detected via magnetic resonance imaging
(MRI) during a regular cancer follow-up. In the mean-
time he had developed an arterial hypertension that was
well controlled with ramipril 5 mg once daily. On admis-
sion he reported no weight loss, no fever, no sweating,
and no signs of icterus or pruritus. His clinical examin-
ation was without any pathological finding.
Diagnostics
Contrast sonography showed a hypertrophia of his left
liver lobe with status post-right hemihepatectomy and no
pathological findings. Computed tomography showed a
dilatation of the residual common bile duct and normal
size pancreatic duct and a contrast enhancement next to
the papilla of Vater leading to the suspicion of an intra-
ductal tumor. There were no signs of metastasis (Fig. 2).
On macroscopic examination, an ERCP supported the
suspicion of an adenocarcinoma in his distal residual
common bile duct. The pathology of the biopsy came
back positive for an adenocarcinoma. An analysis of
serum tumor markers (CA 19-9, CA 72-4, CA 125, and
CEA) showed no elevation.
Treatment
He was treated with a pylorus-preserving resection of
his pancreas head and his duodenum. Postoperatively,
he recovered well. Oral nutrition with low amounts of
fluids were started on day 1 and escalated up to solid
food on day 5. He was discharged on day 14. A 6 French
pancreatic drain that was placed intraoperatively was
removed on day 30 during an ambulatory visit.
In addition, he received adjuvant chemotherapy with
gemcitabine (1000 mg/m2 at day 1, 8, and 15 every 4
weeks) as monotherapy. Chemotherapy was planned for
6 months but discontinued after 3 months due to head
aches and weight loss. As of April 2016, there are no
signs of tumor recurrence during follow-up.
Pathology
A pancreatoduodenectomy was performed and on
macroscopic exploration there was a 1×1×1 cm tumor at
the ampullary region involving his common bile duct.
Histologic examination revealed a tubular and papillary
growth pattern (Fig. 1). The tumor was similar to the
tumor described in his case of pCCA. On immunohisto-
chemistry, the tumor cells expressed cytokeratin (CK) 7
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and CA 19-9. The resection margins were free and the
tumor was staged as pT2 pN0 (0/14) R0, G2.
Molecular pathology
Targeted next-generation sequencing (NGS) was per-
formed on formalin-fixed paraffin-embedded (FFPE)
samples of both cases as described before [13]. Isolated
DNA (<0.5 to 97.6 ng/μl) was amplified with an in-
house specified, customized Ion AmpliSeq Primer Pool.
The panel comprises amplicons of 12 different genes.
Polymerase chain reaction (PCR) products were ligated
to adapters and enriched for target regions using the Ion
AmpliSeq Panel™ Library kit according to the manufac-
turer’s instructions (Life Technologies). The generated
libraries were equimolar pooled for amplicon sequencing
to a concentration of 20 nM of each sample to counter-
balance differences in sample quality. Sequencing was
performed on an Illumina MiSeq benchtop sequencer
(Illumina, San Diego, USA). Results were visualized in
the Integrative Genomics Viewer (IGV) and manually
analyzed. A 5 % cutoff for variant calls was used and
results were only interpreted if the coverage was >100.
Both tumors were analyzed as described and the results
are shown in Table 1. An identical activating mutation
of the PIK3CA gene exon 20 was found in both tumors.
Discussion
A literature research revealed only a few cases compar-
able to our case. Nakahira et al. [14] reported a study
with two cases of lower bile duct recurrence after hepa-
tectomy for pCCA. In contrast to our case, both patients
showed a recurrence after less than 18 months [14],
indicating that both recurrences derived from residual
cells after the first surgery.
There are several case reports showing that intramuco-
sal tumor residuals after resection might lead to recur-
rences of the tumor especially at the side of anastomosis
[15–17]. A case report from Thomas and Heaton [12]
shows that even after 8 years a recurrence of the tumor is
possible. In contrast to our case, their patient presented
with metastatic disease and no primary was found [12].
Jang et al. [18] evaluated the outcome after surgical
resection for extrahepatic CCA. Of the treated patients,
29 % survived 5 years without recurrences of the dis-
ease. At 5 years, 3, 4 % of the treated patients had a re-
currence of the cancer with only one patient presenting
with a limited disease acceptable for surgery.
The case presented here shows an example of a patient
developing a secondary tumor in the same environment
but anatomically distant 9 years after the primary diag-
nosis of pCCA. The identical mutation pattern and the
absence of the most frequent gene alterations [19] in both
Fig. 1 Microscopic examinations. a, b showing microscopic examination of the perihilar cholangiocarcinoma; c, d showing microscopic examination
of the cholangiocarcinoma of the distal bile duct. a Adenocarcinoma arising from the bile duct in a large portal tract with stroma invasion. b On
higher magnification it shows a moderately differentiated adenocarcinoma with a tubular, cribriform, and solid pattern of growth. c Examination of the
papillary region showing pancreatic tissue in the upper left quadrant and infiltration into the papillary region by an adenocarcinoma. d On higher
magnification it shows a poorly differentiated adenocarcinoma with tubular, cribriform, and solid growth pattern
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tumors indicate that the second tumor is very likely a re-
currence of the first. One reason for the long disease-free
interval could be the tumor genetics. Neither a KRAS mu-
tation nor a TP53 mutation was detected, which are both
linked to a worse outcome [19].
With the ongoing development of phosphoinositide 3-
kinase (PI3Kinase)-specific inhibitors as targeted therapy
for tumors with activating mutations in the PIK3CA
gene as in our case, further treatment options might be
available in the future [20].
Table 1 Targeted next-generation sequencing of both tumors showing the same results with an identical activating mutation in the
PIK3CA gene exon 20
Gene Exon Codon Mutation Interpretation
BRAF 15 582–612 Wildtype
DDR2 3–18 1–342, 351–395, 432–586, 620–856 Wildtype
ERBB2 8, 19–21 302–321, 761–881 Wildtype
HRAS 2–4 1–35, 41–82, 105–150 Wildtype
KEAP1 2–6 1–34, 37–122, 127–437, 443–625 Wildtype
KRAS 2–4 4–66, 111–150 Wildtype
NFE2L2 2 16–104 Wildtype
NRAS 2–4 1–32, 45–83, 110–150 Wildtype
PIK3CA 1, 4, 7, 9, 20 66–117, 312–350, 418–435, 521–554, 980–1069 EX20: c.3140A>G p.H1047R activating
PTEN 1–9 1–34, 39–267, 275–333, 343–366 Wildtype
RHOA 2, 3 3–89 Wildtype
TP53 5–9 133–260, 263–331 Wildtype
Fig. 2 a Magnetic resonance imaging scan showing a contrast-enhanced mass in the pancreatic head (arrow). b Magnetic resonance
cholangiopancreatography showing signal loss of the bile duct (shown by white arrow). c Computed tomography scan showing a mass
near the papilla of Vater (arrow). d Computed tomography scan showing the dilation of the residual main bile duct (arrow)
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Conclusion
Late and far distant recurrence of CCA in long-time
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